Hims & Hers Health, Inc. Class A Common Stock (HIMS)
28.84
+0.40 (1.41%)
NYSE· Last Trade: Sep 2nd, 12:05 PM EDT
Detailed Quote
Previous Close
28.44
Open
28.33
Bid
28.83
Ask
28.85
Day's Range
28.15 - 29.36
52 Week Range
13.74 - 65.30
Volume
3,240,713
Market Cap
5.54B
PE Ratio (TTM)
56.55
EPS (TTM)
0.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
12,611,481
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) common stock between August 4, 2025 and July 29, 2026, inclusive (the “Class Period”). Hims & Hers Health, Inc. investors have until November 2, 2026 to file a lead plaintiff motion.
Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). Hims operates a health and wellness platform that connects consumers to licensed healthcare professionals.
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NASDAQ: HIMS) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Glancy Prongay Wolke & Rotter LLP (“GPWR”), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Velanki v. Hims & Hers Health, Inc. et al., 26-cv-09313, on behalf of persons and entities that purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced it is now serving customers in Australia, marking the company's first-ever presence in the Asia-Pacific market. The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of Pilot, Eucalyptus' men's health platform, marking the first Eucalyptus brand to transition to the Hims brand.
PHILADELPHIA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) (“Hims & Hers” or the “Company”) for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation is focused on whether the Company improperly shared private user health data with advertisers, engaged in deceptive billing practices, and made subscription cancellations unnecessarily difficult.
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Hims & Hers Health (NYSE:HIMS...
Check out the companies making headlines yesterday: Funko (NASDAQ:FNKO): Pop culture collectibles manufacturer Funko (NASDAQ:FNKO) rose by 4.9% on Monday aft...
What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 9.2% in the afternoon session after Bloomberg reported that Visa enrolled the...
Visa placed Hims & Hers Health into its Acquirer Monitoring Program after a billing dispute spike, adding penalty costs amid an FTC lawsuit and margin contraction.
Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Hims & Hers Health, Inc. (NYSE: HIMS) failed to manage Hims & Hers in an acceptable manner, breaching their fiduciary duties to Hims & Hers, and whether Hims & Hers and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know:
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) To Contact Him Directly To Discuss Their Options
RADNOR, PA - August 19, 2026 (NEWMEDIAWIRE) - Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased or acquired Hims & Hers Health, Inc. securities and experienced significant financial losses.
